Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alginate-coated folic acid-functionalized selenium nanoparticles are an experimental targeted nanotherapeutic system designed for cancer therapy. This formulation utilizes a selenium nanoparticle (SeNP) core, which possesses intrinsic antineoplastic properties by inducing reactive oxygen species (ROS) and triggering mitochondrial-mediated apoptosis in cancer cells. The surface of the nanoparticles is functionalized with folic acid (Vitamin B9) to exploit the overexpression of folate receptors (particularly folate receptor alpha) on the surface of various malignant cells, such as those in breast, lung, and ovarian cancers. This targeting mechanism facilitates receptor-mediated endocytosis, increasing the intracellular concentration of selenium within the tumor while sparing healthy tissues. The alginate coating, a biocompatible polysaccharide, provides colloidal stability, prevents nanoparticle aggregation in physiological environments, and can be engineered for pH-responsive release of the selenium core or other encapsulated chemotherapeutic agents in the acidic tumor microenvironment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alginate-coated folic acid-functionalized selenium nanoparticles.